Novo Nordisk (GB:0QIU)
LSE:0QIU
Holding GB:0QIU?
Track your performance easily

Novo Nordisk (0QIU) Share Forecast & Price Target

34 Followers
See the Price Targets and Ratings of:

0QIU Analyst Ratings

Moderate Buy
13Ratings
8 Buy
3 Hold
2 Sell
Based on 13 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr950.62
▲(7.76% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr950.62 with a high forecast of kr1,200.00 and a low forecast of kr560.00. The average price target represents a 7.76% change from the last price of kr882.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"559":"kr559","880":"kr880","1201":"kr1,201","719.5":"kr719.5","1040.5":"kr1,040.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr1.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":950.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr950.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":560,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr560.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[559,719.5,880,1040.5,1201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Mar<br/>2024","9":"Jun<br/>2024","12":"Sep<br/>2024","25":"Sep<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,885.82,909.9876923076923,934.1553846153846,958.323076923077,982.4907692307693,1006.6584615384616,1030.8261538461538,1054.993846153846,1079.1615384615384,1103.329230769231,1127.4969230769232,1151.6646153846154,1175.8323076923077,{"y":1200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,885.82,890.8046153846154,895.7892307692308,900.7738461538462,905.7584615384616,910.743076923077,915.7276923076923,920.7123076923077,925.6969230769231,930.6815384615385,935.6661538461539,940.6507692307692,945.6353846153846,{"y":950.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,885.82,860.7569230769232,835.6938461538462,810.6307692307693,785.5676923076924,760.5046153846154,735.4415384615385,710.3784615384616,685.3153846153846,660.2523076923077,635.1892307692308,610.1261538461538,585.0630769230769,{"y":560,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":659.12,"date":1694736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637.78,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":674.17,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":690.96,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":716.74,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":779.82,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":841.56,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":859.77,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":839.98,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":980.19,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":970.23,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":892.68,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":885.82,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr1,200Average Price Targetkr950.62Lowest Price Targetkr560.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
kr560
Sell
-36.52%
Downside
Reiterated
08/07/24
Bernstein Remains a Sell on Novo Nordisk (0QIU)
Citi
kr975
Buy
10.52%
Upside
Reiterated
08/05/24
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)Citi analyst Peter Verdult reiterated a Buy rating and DKK975.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
DNB Markets
kr1,200
Buy
36.02%
Upside
Reiterated
06/27/24
DNB Markets Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)DNB Markets analyst Rune Majlund Dahl reiterated a Buy rating and DKK1,200.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
Bank of America Securities
kr1,025kr1,150
Buy
30.36%
Upside
Reiterated
06/14/24
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,150 at BofA SecuritiesBofA Securities analyst Sachin Jain raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,150.00 (from DKK1,025.00) while maintaining a Buy rating.
DZ BANK AG
Hold
Reiterated
05/03/24

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy GB:0QIU and Sell After:
1 Month
xxx
Success Rate
32/49 ratings generated profit
65%
Average Return
+2.66%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.31% of your transactions generating a profit, with an average return of +2.66% per trade.
3 Months
xxx
Success Rate
36/49 ratings generated profit
73%
Average Return
+8.47%
reiterated a xxx
rating 23 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.47% of your transactions generating a profit, with an average return of +8.47% per trade.
1 Year
Richard VosserJ.P. Morgan
Success Rate
44/49 ratings generated profit
90%
Average Return
+34.05%
reiterated a buy rating 9 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 89.80% of your transactions generating a profit, with an average return of +34.05% per trade.
2 Years
xxx
Success Rate
44/49 ratings generated profit
90%
Average Return
+52.76%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.80% of your transactions generating a profit, with an average return of +52.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Strong Buy
0
0
0
0
0
Buy
19
21
28
24
18
Hold
11
9
10
7
10
Sell
1
2
3
4
3
Strong Sell
0
0
0
0
0
total
31
32
41
35
31
In the current month, 0QIU has received 18 Buy Ratings, 10 Hold Ratings, and 3 Sell Ratings. 0QIU average Analyst price target in the past 3 months is kr950.62.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr6.05 with a range of kr5.63 to kr6.52. The previous quarter’s EPS was kr4.49. 0QIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.55% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.
Next quarter’s earnings estimate for 0QIU is kr6.05 with a range of kr5.63 to kr6.52. The previous quarter’s EPS was kr4.49. 0QIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 34.55% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr73.81B with a range of kr71.60B to kr76.98B. The previous quarter’s sales results were kr68.06B. 0QIU beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.
Next quarter’s sales forecast for 0QIU is kr73.81B with a range of kr71.60B to kr76.98B. The previous quarter’s sales results were kr68.06B. 0QIU beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is kr950.62.
    What is GB:0QIU’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 7.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novo Nordisk a Buy, Sell or Hold?
          Novo Nordisk has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 3 hold ratings and 2 sell ratings.
            What is Novo Nordisk’s share price target?
            The average share price target for Novo Nordisk is kr950.62. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr1,200.00 ,and the lowest forecast is kr560.00. The average share price target represents 7.76% Increase from the current price of kr882.2.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Novo Nordisk?
                To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis